Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolf Larsson

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Expert Opinion on Medical Diagnostics|March 19, 2013
Predictive tests for individualization of pharmacological cancer treatmentPeter Nygren, Rolf Larsson
Acta Oncologica (Stockholm, Sweden)|October 29, 2013
Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancerPeter Nygren, Rolf Larsson
Molecular Cancer Therapeutics|May 14, 2004
Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828Henrik Lövborg, Peter Nygren, Rolf Larsson
Nature Protocols|August 21, 2008
The fluorometric microculture cytotoxicity assayElin Lindhagen, Peter Nygren, Rolf Larsson
Anticancer Research|August 15, 2002
Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cellsSara Ekelund, Rolf Larsson, Peter Nygren
Anti-Cancer Drugs|June 3, 2005
Screening for apoptosis--classical and emerging techniquesHenrik Lövborg, Joachim Gullbo, Rolf Larsson
Electrophoresis|February 22, 2008
Towards high-throughput single cell/clone cultivation and analysisSara Lindström, Rolf Larsson, Helene Andersson Svahn
BMC Cancer|July 9, 2013
Effects of hypoxia on human cancer cell line chemosensitivitySara Strese, Mårten Fryknäs, Rolf Larsson, et al.
Journal of Cancer Research and Clinical Oncology|October 19, 2013
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancerPeter Nygren, Mårten Fryknäs, Bengt Agerup, et al.
Anti-Cancer Drugs|June 3, 2005
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancerKenneth Villman, Carl Blomqvist, Rolf Larsson, et al.
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Expert Opinion on Medical Diagnostics|March 19, 2013
Predictive tests for individualization of pharmacological cancer treatmentPeter Nygren, Rolf Larsson
Acta Oncologica (Stockholm, Sweden)|October 29, 2013
Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancerPeter Nygren, Rolf Larsson
Molecular Cancer Therapeutics|May 14, 2004
Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828Henrik Lövborg, Peter Nygren, Rolf Larsson
Nature Protocols|August 21, 2008
The fluorometric microculture cytotoxicity assayElin Lindhagen, Peter Nygren, Rolf Larsson
Anticancer Research|August 15, 2002
Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cellsSara Ekelund, Rolf Larsson, Peter Nygren
Anti-Cancer Drugs|June 3, 2005
Screening for apoptosis--classical and emerging techniquesHenrik Lövborg, Joachim Gullbo, Rolf Larsson
Electrophoresis|February 22, 2008
Towards high-throughput single cell/clone cultivation and analysisSara Lindström, Rolf Larsson, Helene Andersson Svahn
BMC Cancer|July 9, 2013
Effects of hypoxia on human cancer cell line chemosensitivitySara Strese, Mårten Fryknäs, Rolf Larsson, et al.
Journal of Cancer Research and Clinical Oncology|October 19, 2013
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancerPeter Nygren, Mårten Fryknäs, Bengt Agerup, et al.
Anti-Cancer Drugs|June 3, 2005
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancerKenneth Villman, Carl Blomqvist, Rolf Larsson, et al.
Pageof 18